Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CSL Behring LLC
Sponsor

CSL Behring LLC

United States 1020 1st Avenue, 19406-1310, United States

About the sponsor

Research activity includes haemophilia B and Hemophilia B, with a strong emphasis on AAV-based gene therapy, factor IX expression, and long-term control of bleeding risk in adolescent and adult populations.

  • Factor IX replacement
  • Bleeding prevention
  • AAV vector therapy
  • Long-term safety follow-up

Clinical interest also extends to neutralizing antibodies and sustained treatment outcomes after gene-based intervention.

About Specializations

CSL Behring LLC runs clinical trials in conditions such as Factor IX deficiency, Hereditary angioedema, Arteriosclerosis, Alpha-1 antitrypsin deficiency, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

17 clinical trials

Arteriosclerosis

Recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Alpha-1 antitrypsin deficiency

Recruiting
Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Human Alpha1-Proteinase Inhibitor
  • Sponsor:CSL Behring LLC

A study to assess the safety of Anumigilimab in adults with sickle cell disease

Recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ANUMIGILIMAB
  • Sponsor:CSL Behring LLC

Hereditary haemochromatosis

Recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:VAMIFEPORT TRIHYDROCHLORIDE
  • Sponsor:CSL Behring LLC

Factor IX deficiency

Recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Etranacogene Dezaparvovec
  • Sponsor:CSL Behring LLC

Factor IX deficiency

Recruiting
Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Etranacogene Dezaparvovec
  • Sponsor:CSL Behring LLC

Bronchiectasis

Not yet recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Dermatomyositis

Not recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Hereditary angioedema

Not recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Garadacimab
  • Sponsor:CSL Behring LLC

Postural orthostatic tachycardia syndrome

Not recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Plasma Protein
  • Sponsor:CSL Behring LLC

Sickle cell anaemia with crisis

Not recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:HEMOPEXIN, HUMAN
  • Sponsor:CSL Behring LLC

Factor IX deficiency

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Etranacogene Dezaparvovec
  • Sponsor:CSL Behring LLC

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.